The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies, particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness, improved ...

Collection of ethnicity data in clinical research has been poor historically, but is essential to ensure that interventions are effective and safe across diverse populations. These data are needed to ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Moderna and Merck will start a phase 3 trial of the combination in adjuvant melanoma therapy later this year, and the proof-of-concept for this personalised neoantigen vaccine approach means that ...